Condition: The Efficacy and Safety of SBRT in MPLC · Sponsor: Fang Wu
To prospectively evaluate the effectiveness and safety of SBRT in the treatment of residual malignant pulmonary nodules after lung cancer, and is committed to providing new treatment options for patients with multiple primary malignant pulmonary nodules who cannot tolerate multiple operations.
This description comes directly from the study's public registry record.
Chunhong Hu, professor · +86 13508486908 · huchunh5829@126.com
Always discuss trial participation with your own doctor first.
| Oncology Department，Second Xiangya Hospital of Central South University | Changsha, Hunan, China | Recruiting |
| Hunan Cancer Hospital | Changsha, China | Recruiting |
| The Third Xiangya Hospital, Central South University | Changsha, China | Recruiting |
| Xiangya Hospital, Central South University | Changsha, China | Recruiting |
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05113017